Literature DB >> 6994775

Pharmacokinetics and metabolism of guanfacine in man: a review.

J R Kiechel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6994775      PMCID： PMC1430131          DOI： 10.1111/j.1365-2125.1980.tb04901.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  3 in total

1.  Arene oxides: a new aspect of drug metabolism.

Authors:  D M Jerina; J W Daly
Journal:  Science       Date:  1974-08-16       Impact factor: 47.728

2.  Guanfacine kinetics in patients with hypertension.

Authors:  Y A Weiss; D L Lavene; M E Safar; A C Simon; Y Loria; D R Georges; P L Milliez
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

3.  Determination of guanfacine in biological fluids by electron-capture GLC.

Authors:  M Guerret; D Lavene; J Longchampt; J L Kiger
Journal:  J Pharm Sci       Date:  1979-02       Impact factor: 3.534
  3 in total
  16 in total

1.  Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder.

Authors:  Martin P Cruz
Journal:  P T       Date:  2010-08

2.  Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients.

Authors:  William Knebel; Mary Corcoran; James Ermer; Marc R Gastonguay
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

3.  Disrupted in schizophrenia 1 modulates medial prefrontal cortex pyramidal neuron activity through cAMP regulation of transient receptor potential C and small-conductance K+ channels.

Authors:  Lynda El-Hassar; Arthur A Simen; Alvaro Duque; Kiran D Patel; Leonard K Kaczmarek; Amy F T Arnsten; Mark F Yeckel
Journal:  Biol Psychiatry       Date:  2014-01-20       Impact factor: 13.382

4.  Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Guanfacine Extended-Release Formulation in Healthy Japanese and Caucasian Male Adults.

Authors:  Yumiko Matsuo; Masafumi Okita; James Ermer; Toshihiro Wajima
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

5.  Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure.

Authors:  J R Kiechel; D Lavene; M Guerret; E Comoy; M Godin; J P Fillastre
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Pharmacokinetics of guanfacine in patients undergoing haemodialysis.

Authors:  W Kirch; H Kohler; T Axthelm
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

7.  Clinical experience with guanfacine in long-term treatment of hypertension.

Authors:  P Jerie
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

Review 8.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

9.  Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.

Authors:  Nicole M Barcelos; Peter H Van Ness; Allison F Wagner; Martha G MacAvoy; Adam P Mecca; George M Anderson; Mark Trentalange; Keith A Hawkins; Mary Sano; Amy F T Arnsten; Christopher H van Dyck
Journal:  Neurobiol Aging       Date:  2018-05-31       Impact factor: 4.673

Review 10.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.